• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman

    12/4/24 9:00:00 AM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology
    Get the next $AIFF alert in real time by email

    TORONTO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of current director of the Board, Greg Lipschitz, as Executive Chairman, effective as of December 3, 2024.

    "I look forward to taking on a more active leadership role as Executive Chairman," said Greg Lipschitz, newly appointed Executive Chairman of Firefly. "I believe that Firefly is uniquely positioned at the intersection of artificial intelligence and brain health that I have long been passionate about, and I look forward to continuing my journey with the Company in this next chapter."

    Mr. Lipschitz has served as Firefly's director since December 2022. Mr. Lipschitz has over 13 years of combined experience in private equity, merchant banking, capital markets and finance. From June 2018 to February 2024, Mr. Lipschitz served as the Vice President of Lazer Capital. He currently serves as the Managing Director of Old Stone Advisors, a financial advisory firm. Mr. Lipschitz has advised on over $1 billion of transactions. He is a Chartered Financial Analyst and received his bachelor's degree in business from the Richard Ivey Business School at the University of Western Ontario.

    Firefly's Board of Directors welcomed Mr. Lipschitz to the new expanded role and commented, "Greg brings extensive capital markets knowledge to the Company and has been a valuable asset in moving the Company agenda forward over the last three years. At this critical juncture heading into the new year as we commercialize our technology, the Board has decided that it is in the best interest of the Company and our shareholders to transition him to the Executive Chairman role."

    Mr. David Johnson has resigned from the board of Firefly and stepped down as its Executive Chairman, effective as of November 30, 2024. This was not the result of any disagreement between Mr. Johnson and the Company, its management, the Board or any committee of the Board on any matter relating to the Company's operations, policies or practices, or any other matter.

    The Firefly board also thanked Mr. Johnson for his contributions to the Company and wished him well in his future endeavors.

    About Firefly

    Firefly (NASDAQ:AIFF) is an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly's FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.

    Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly's extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician's ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient's outcome.

    Please visit https://fireflyneuro.com/ for more information.

    Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly's management teams' expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to development and commercialization of BNATM technology; risks related to Firefly's ability to recognize the anticipated benefits of the merger (the "Merger") with WaveDancer, Inc. ("WaveDancer"); risks related to Firefly's ability to correctly estimate its operating expenses and unanticipated spending and costs that could reduce Firefly's cash resources; the ability of Firefly to protect its intellectual property rights; competitive responses to the Merger; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those factors described under the heading "Risk Factors" in the in the registration statement on Form S-4 filed by WaveDancer with the Securities and Exchange Commission on January 22, 2024, as amended, and declared effective on February 6, 2024. Should one or more of these risks or uncertainties materialize, or should any of Firefly's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

    Investor Contact

    KCSA Strategic Communications

    Valter Pinto or Jack Perkins

    (212) 896-1254

    [email protected]

    Media Contact

    KCSA Strategic Communications

    Raquel Cona, Vice President

    (516) 779-2630

    [email protected]



    Primary Logo

    Get the next $AIFF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • Who has been appointed as the Executive Chairman of Firefly Neuroscience?

      Greg Lipschitz has been appointed as the Executive Chairman of Firefly Neuroscience, effective December 3, 2024, after serving as a director on the Board since December 2022.

    • What relevant experience does Greg Lipschitz bring to his new role as Executive Chairman?

      Mr. Lipschitz has extensive experience in private equity, merchant banking, capital markets, and finance, which includes advising on over $1 billion of transactions.

    • Who resigned from the board of Firefly and what was the nature of his departure?

      David Johnson has resigned from the board of Firefly and stepped down as Executive Chairman as of November 30, 2024. His resignation was not due to any disagreements with the Company or its management.

    • What are the primary goals and focus areas of Firefly Neuroscience?

      Firefly is focused on developing AI solutions that improve brain health outcomes, particularly for patients with neurological and mental disorders, and is commercializing its FDA-cleared Brain Network Analytics (BNA™) technology.

    • How does Firefly's Brain Network Analytics (BNA™) technology enhance clinical diagnosis and treatment?

      Firefly's BNA™ technology utilizes a proprietary database of standardized EEGs from over 17,000 patients to enhance diagnosis and treatment of mental and cognitive disorders.

    Recent Analyst Ratings for
    $AIFF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIFF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

      A correction from source is being issued with respect to the press release titled, Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc., released on May 5, 2025 at 8:00 am ET. Please note, the correct form of payment of the potential Evoke investors' earn-out is in Firefly's common stock. The complete corrected press release follows: Builds upon Firefly's recent acceptance into the NVIDIA Connect program Marks next major step toward building a proprietary foundation model of the human brain KENMORE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," or the "Company")

      5/5/25 9:00:00 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

      Builds upon Firefly's recent acceptance into the NVIDIA Connect program Marks next major step toward building a proprietary foundation model of the human brain KENMORE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce its acquisition of Evoke Neuroscience, Inc. ("Evoke"), a medical device company developing and commercializing technologies to aid in the comprehensive assessment of brain health. The transaction marks another important step toward

      5/5/25 7:45:00 AM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million

      KENMORE, N.Y., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announced that it has received total proceeds of $8,824,710 from the exercise of warrants to purchase 823,530 shares of the common stock of the Company, par value $0.0001 per share ("common stock"), at an exercise price of $6.83, and warrants to purchase 800,000 shares of commons stock, at an exercise price of $4.00, respectively. The warrants were issued pursuant to private placements that closed

      2/21/25 8:00:00 AM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology

    $AIFF
    Leadership Updates

    Live Leadership Updates

    See more
    • Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman

      TORONTO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of current director of the Board, Greg Lipschitz, as Executive Chairman, effective as of December 3, 2024. "I look forward to taking on a more active leadership role as Executive Chairman," said Greg Lipschitz, newly appointed Executive Chairman of Firefly. "I believe that Firefly is uniquely positioned at the intersection of artificial intelligence and brain health that I have l

      12/4/24 9:00:00 AM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors

      TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of Stella Vnook, Ph.D. to its Board of Directors, effective as of August 19, 2024. Dr. Vnook will serve as Chairperson of the Nominating Committee. Dr. Vnook brings over 25 years of experience as a distinguished pharmaceutical executive, serial entrepreneur, CEO and founder of multiple biotech companies and visionary leader with a track record of success in biotechnology and life

      9/5/24 9:00:00 AM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology

    $AIFF
    SEC Filings

    See more
    • SEC Form 10-Q filed by Firefly Neuroscience Inc.

      10-Q - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

      5/14/25 6:02:18 AM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • Firefly Neuroscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

      5/5/25 6:20:09 AM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • Firefly Neuroscience Inc. filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

      4/24/25 3:51:32 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology

    $AIFF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO Lipschitz Gregory

      4 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

      4/22/25 7:09:21 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by President and COO Decaprio David

      4 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

      4/22/25 7:08:38 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • New insider Issachar Gil claimed ownership of 33,480 shares (SEC Form 3)

      3 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

      3/19/25 6:30:52 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology

    $AIFF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Firefly Neuroscience Inc.

      SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)

      9/19/24 9:48:56 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G filed by Firefly Neuroscience Inc.

      SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)

      8/21/24 6:07:51 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G filed by Firefly Neuroscience Inc.

      SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)

      8/21/24 6:03:49 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology

    $AIFF
    Financials

    Live finance-specific insights

    See more
    • Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update

      Company successfully listed on Nasdaq under the symbol "AIFF" Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company's dual go-to-market strategy TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced its financial results for the third quarter ended September 30, 2024, and provided a stockholder update. Firefly is dedicated to improving outcomes for people suffering wi

      11/14/24 5:30:18 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology